M50054

M50054 is a potent inhibitor of apoptosis. M50054 inhibits Etoposide-induced caspase-3 activation of U937 cells with an IC₅₀ of 79 μg/mL. M50054 does not directly inhibit the enzymatic activity of caspase-3. M50054 can be used for the research anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia^[1]. In Vitro: M50054 inhibits the caspase-3 activation by Etoposide in a dose-dependent manner. The IC₅₀ value of M50054 against Etoposide-induced caspase-3 activation of U937 cells is 79 μg/mL. However, M50054 does not directly inhibit the enzymatic activity of caspase-3 at all concentrations up to 1000 μg/mL^[1].
M50054 (1-300 μg/mL) inhibits soluble human Fas ligand-induced cell death of human Fas-expressing WC8 cells in a dose-dependent manner, and the IC₅₀ of 67 μg/mL^[1].
M50054 (30-300 μg/mL) inhibits the death of U937 cells induced by etoposide (10 μg/mL) in a dose-dependent manner, and the IC₅₀ value of M50054 against Etoposide-induced cell death of U937 cells is 130 μg/mL. The IC₅₀ value of M50054 against etoposide-induced DNA fragmentation of U937 cells was 54 μg/mL^[1]. In Vivo: M50054 (10-300 mg/kg; oral administration 30 min before anti-Fas antibody injection) inhibits the elevation of alanine aminotransferase and aspartate aminotransferase in a dose-dependent manner^[1].
M50054 (topical treatment; given daily beginning on day 5 after birth and ending on day 14) significantly improves alopecia (hair loss) symptoms^[1].